Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Among 63 patients who were treated with rituximab (Rituxan), remission or partial responses at 1 year were observed in 49% and 24% of patients, respectively, reported Benjamin Terrier, MD, PhD, of Université Paris Descartes in Paris, and colleagues.
In addition, as shown in the team’s study online in Arthritis & Rheumatology, among the 51 patients who had received mepolizumab (Nucala), remission or partial response at 1 year was seen in 78% and 10%, respectively. Remission or partial response was seen in only 15% and 33% of the 33 patients treated with omalizumab (Xolair).
EGPA is a small-vessel vasculitis characterized by asthma, sinusitis, and blood and tissue eosinophilia, with a subset of patients also positive for antineutrophil cytoplasmic antibodies (ANCA). Traditional therapy has relied on glucocorticoids and conventional immunosuppressants, but relapses are common and long-term use of steroids carries significant risk.
“Because EGPA shares pathophysiological features with other ANCA-associated vasculitides, eosinophilic disorders, and asthma, alternative therapeutic options may be considered in EGPA, especially rituximab (monoclonal anti-CD20 antibody), omalizumab (monoclonal anti-IgE antibody) and mepolizumab (monoclonal anti-IL[interleukin]-5 antibody),” the researchers wrote.
Rituximab is indicated for use in rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, and omalizumab is indicated for asthma and chronic idiopathic urticaria.
Mepolizumab was approved for the treatment of EGPA in the U.S. in December 2017 after efficacy was demonstrated in a phase III trial, but has not been approved for this indication in Europe.
To examine the European experience with these agents, Terrier and co-authors conducted a collaborative study of patients who had received biologic therapy for vasculitis flares, refractory eosinophilic asthma, and ear, nose, and throat manifestations.
Remission was defined as a Birmingham Vasculitis Activity Score (BVAS) of zero and a daily prednisone dose of 5 mg or less, and partial response was a score of zero and prednisone dose of 6-10 mg/day. Outcomes other than remission and partial response included treatment failure and stopping treatment due to adverse events.
Rituximab was given in doses of 1,000 mg 2 weeks apart or 375 mg/m2/week for four infusions; mepolizumab was given in monthly doses of 100 or 300 mg. Omalizumab typically is given every 2 or 4 weeks, with dosing determined according to patient age, weight, and IgE level, the researchers noted.
Rituximab was most commonly given for vasculitis flares, although these were often accompanied by asthma, while mepolizumab and omalizumab were initiated for glucocorticoid-dependent asthma and ear, nose, and throat manifestations.
Among the rituximab-treated group, the median BVAS declined from 8.5 at baseline to 1 at 6 months and 0 at 12 months, and median prednisone dosages declined from 20 mg/day to 7.5 mg/day at 6 and 12 months, respectively. Therapeutic failure was observed in 24% of patients and withdrawal due to adverse events in 3%.
Remission was reported in 59% of patients who were ANCA positive and 41% of those who were